AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Adjuvant licensed for the development of HIV vaccine.
2003 NOV 5 - (NewsRx.com & NewsRx.net) -- The Immune Response Corporation (IMNR) and Hybridon, Inc., (HYBN) have entered into a license agreement for the use of Amplivax as an adjuvant in the development of a novel vaccine candidate for the prevention and treatment of human immunodeficiency virus (HIV).
The new vaccine candidate, which has already demonstrated activity in laboratory experiments, combines the whole-killed vaccine technology employed in Remune, an immune-based HIV therapeutic vaccine being evaluated in phase II clinical trials by The Immune Response Corporation, plus Amplivax, Hybridon's second-generation immunomodulatory oligonucleotide (IMO) adjuvant designed to enhance the immune response to a vaccine antigen.
The Immune Response Corporation separately will continue its clinical development of Remune as a potential treatment for patients already infected with the HIV virus.
"As The Immune Response Corporation presses forward with the clinical development of Remune, we intend to expand our efforts in the HIV area by beginning development of the new vaccine candidate for broader prophylactic and therapeutic applications," said John Bonfiglio, PhD, chief executive officer of The Immune Response Corporation.
"In preclinical data generated to date, the use of Remune plus Amplivax has elicited a significantly enhanced ...
- The Immune Response Corporation Announces Acquisition Of T Cell Receptor...
- Press release article from: PR Newswire December 13, 1999 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) today...intellectual property to The Immune Response Corporation, in exchange for cash, stock and royalties. The Immune Response Corporation owns additional TCR...
- Connetics and XOMA Sell T Cell Receptor Technology to the Immune Response...
- Press release article from: Business Wire December 13, 1999 700+ words
...intellectual property to The Immune Response Corporation (IRC, Nasdaq:IMNR...stock and royalties. The Immune Response Corporation owns additional TCR...and common stock of The Immune Response Corporation, as well as royalties...
- THE IMMUNE RESPONSE CORPORATION'S LICENSED B CELL LYMPHOMA TECHNOLOGY RECEIVES...
- Press release article from: PR Newswire April 25, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced...exclusively licensed to The Immune Response Corporation. This technology provides...Kimmel Cancer Center. The Immune Response Corporation is a biopharmaceutical...
- THE IMMUNE RESPONSE CORPORATION'S LICENSED TECHNOLOGY SHOWN TO ERADICATE BRAIN...
- Press release article from: PR Newswire April 2, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) today...collaborative effort between The Immune Response Corporation and SKCC has already...Executive Officer of The Immune Response Corporation. "We believe this technology...
- THE IMMUNE RESPONSE CORPORATION COMPLETES ENROLLMENT OF PHASE II CLINICAL TRIAL...
- Press release article from: PR Newswire March 12, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced...executive officer of The Immune Response Corporation. "We are excited about...debilitating disease." The Immune Response Corporation is a biopharmaceutical...
- THE IMMUNE RESPONSE CORPORATION'S LICENSED TECHNOLOGY RECEIVES U.S. PATENT
- Press release article from: PR Newswire March 14, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced...exclusively licensed to The Immune Response Corporation. This newly patented...therapy programs. The Immune Response Corporation is a biopharmaceutical...
- The Immune Response Corporation Postpones Follow-on Public Offering of Common...
- Press release article from: PR Newswire August 7, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced...executive officer of The Immune Response Corporation. "Immune Response has...less volatile." The Immune Response Corporation is a biopharmaceutical...
- The Immune Response Corporation and NovaRx Corporation Announce Revision of...
- Press release article from: PR Newswire September 8, 2004 700+ words
The Immune Response Corporation , a biopharmaceutical company...agreement to transfer all of The Immune Response Corporation's in-licensed development...NovaRx agreed to pay The Immune Response Corporation the total sum of $1,050...